What dose of CDP choline do studies and labels give?

Strengths and labels
FormStrengthWhere
Oral solution, 10 mL sachet1000 mg per sachet56Spanish regulator reports
Oral solution, 500 mL bottle50 mg/mL citicoline free acid7Glaucoma trial (Rossetti)
Capsule250 mg per capsule1Memory trial (Nakazaki)
Tablet500 mg per tablet, given as 2×500 mg8ICTUS (Dávalos)

Placebo-controlled trials gave 500 mg a day for 12 weeks to 100 healthy adults aged 50 to 85 with age-associated memory impairment (Nakazaki), 250 or 500 mg a day for 28 days to 75 healthy adolescent males (McGlade 2019), a dose stepped up to 2000 mg a day over 12 weeks to 62 adults with alcohol use disorder (Brown), and 2000 mg a day for 90 days to 1213 patients with traumatic brain injury (COBRIT, Zafonte 2012).1234

Strengths and labels

The table is set at the top of the page

The Spanish regulator's reports list the oral solution for neurological and cognitive disorders associated with cerebrovascular accidents and with traumatic brain injuries, and refer the posology to the summary of product characteristics, which was not found.56 No US label for citicoline turned up in DailyMed, and no label or maker's leaflet giving tablet or capsule strengths turned up; the capsule and tablet strengths above come from the memory trial and ICTUS.18 Both liquids are ready-made, and searches located no instruction for mixing a powder. Searches found no injectable product for U-100 syringe use, although ICTUS gave citicoline intravenously and a 509-patient study gave it intramuscularly; both liquids above are measured in mL.89

Doses used in trials

TrialDose and schedulePeopleLength
Memory trial (Nakazaki)500 mg a day as 2 capsules of 250 mg with breakfast, or placebo1100 healthy adults aged 50 to 85 with age-associated memory impairment, 99 completed12 weeks
Adolescent trial (McGlade 2019)250 or 500 mg a day, or placebo21Seventy-five healthy adolescent males, 51 on citicoline and 24 on placebo28 days
Alcohol use disorder trial (Brown)Stepped up to 2000 mg a day, or placebo362 adults aged 18 to 75 with alcohol use disorder, 55 analysed12 weeks
Glaucoma trial (Rossetti)500 mg a day in the morning, as 10 mL of 50 mg/mL, crossed over with placebo7155 patients with chronic open-angle glaucoma enrolled, of 220 planned3 months on one treatment, then 6 months on the other
ICTUS (Dávalos 2012)1000 mg every 12 h intravenously for the first 3 days, then orally as 2×500 mg tablets every 12 h, started within 24 h of symptom onset, or placebo82298 patients with moderate-to-severe acute ischaemic stroke6 weeks in total
COBRIT (Zafonte 2012)2000 mg a day, as 1000 mg twice a day, oral or enteral, first dose within 24 hours of injury, or placebo4101213 patients with complicated mild, moderate or severe traumatic brain injury at 8 US level 1 trauma centers90 days

The alcohol use disorder trial started citicoline at 500 mg/day at baseline and raised it to 1000 mg/day at week 2, 1500 mg/day at week 4 and 2000 mg/day at week 6.3 COBRIT concluded that, among patients with traumatic brain injury, citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status.4 ICTUS was stopped for futility at the third interim analysis, and its authors concluded that, under the circumstances of the trial, citicoline is not efficacious in the treatment of moderate-to-severe acute ischaemic stroke.8

Storage

The Spanish regulator's reports give the oral solution a shelf-life of 3 years and say the medicinal product does not require any special storage conditions; no storage statement for a sachet in use, capsules or tablets is sourced.56

Frequently asked questions

When in the day do trials give citicoline?

The memory trial gave it with breakfast, the glaucoma trial in the morning, and a single-dose study of twelve mildly hypertensive but otherwise normal fasting subjects (Wurtman 2000) gave 500, 2000 or 4000 mg or placebo orally at 8:00 a.m.1711 ICTUS gave doses every 12 h and COBRIT twice a day.810

Is there a cycle of weeks on and weeks off?

Neither Spanish regulator report states one, and the trials in the table ran without breaks; a review (Gareri) describes a 509-patient double-blind crossover study vs placebo, sponsored by Wyeth Lederle in 1998, of 1,000 mg intramuscularly once a day in mild-to-moderate vascular dementia, run as six 21-day cycles with 21 days free of drug in between, three on citicoline and three on placebo.59

Is citicoline absorbed by mouth as well as by injection?

A review (Gareri) describes CDP-choline as water-soluble with >90% bioavailability, and a review (Secades) says absorption by the oral route is virtually complete, so oral bioavailability is approximately the same as intravenous.912

What side effects did trials report?

A review (Gareri) reports that, of 2,817 patients of all ages, mainly aged 60 to 80 with different neurological conditions, 5.01% had side effects, mostly digestive intolerance.9 The 12-week memory trial of 100 adults reported no serious adverse events; one participant in the citicoline group withdrew due to a headache, which was judged as possibly related to study product.1

References

  1. Nutrients (PMC). Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 2021. pmc.ncbi.nlm.nih.gov
  2. J Atten Disord (PubMed). The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. 2019. pubmed.ncbi.nlm.nih.gov
  3. PMC. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder. 2018. pmc.ncbi.nlm.nih.gov
  4. JAMA (PubMed). Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). 2012. pubmed.ncbi.nlm.nih.gov
  5. AEMPS (Spain). Version 10 February 2012. cima.aemps.es
  6. AEMPS (Spain). Version 10 February 2012. cima.aemps.es
  7. Graefes Arch (PMC). The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial. 2023. pmc.ncbi.nlm.nih.gov
  8. Lancet (PubMed). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). 2012. pubmed.ncbi.nlm.nih.gov
  9. PMC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. 2015. pmc.ncbi.nlm.nih.gov
  10. ClinicalTrials.gov. NCT00545662: Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT). 2012. clinicaltrials.gov
  11. PubMed. Effect of oral CDP-choline on plasma choline and uridine levels in humans. 2000. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Citicoline: pharmacological and clinical review, 2006 update. 2006. pubmed.ncbi.nlm.nih.gov